文献速递肺栓塞与肺血管病

RAAS抑制剂与肺动脉高压患者死亡率:VA数据库分析

Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database.
PubMed 文献 · Chest · 2020-10-05

该回顾性队列研究利用美国退伍军人事务部CART数据库,纳入24,221例血流动力学确诊的肺动脉高压患者,分析ACEI、ARB和醛固酮拮抗剂与死亡率的关系。结果显示ACEI和ARB使用与更低死亡率相关,且独立于肺动脉楔压,在毛细血管前PH亚组亦存在;醛固酮拮抗剂使用与更差生存相关,但校正疾病严重度后消失,提示其反映疾病严重程度。

要点

  • ACEI/ARB使用与血流动力学确诊PH患者更低死亡率相关
  • 该关联独立于肺动脉楔压,并在毛细血管前PH亚组中同样存在
  • 醛固酮拮抗剂与更差生存的未校正关联可能源于疾病严重度混杂

核心结论

  • ACEI和ARB使用与退伍军人PH患者更低死亡率相关。
  • 醛固酮拮抗剂使用是PH疾病严重程度的标志。
  • ACEI和ARB可能代表多种PH表型的新治疗策略。

研究设计与样本

  • 回顾性队列研究,使用退伍军人事务部临床评估报告与追踪数据库。
  • 纳入24,221例血流动力学确诊的肺动脉高压患者。
  • 在全队列和倾向性匹配队列中评估关系,并采用分阶段模型校正人口学、社会经济状况、合并症、疾病严重度和合并用药。

主要发现

  • ACEI和ARB使用在全队列和倾向性匹配队列的未校正Kaplan-Meier生存分析中与改善生存相关。
  • 该关系对校正不敏感,独立于肺动脉楔压,并在限于毛细血管前PH的队列中同样观察到。
  • 醛固酮拮抗剂使用在全队列未校正Kaplan-Meier分析中与更差生存相关。
  • 醛固酮拮抗剂在倾向性匹配队列中与死亡率关联较弱,校正疾病严重度后不再与更差生存相关。

临床怎么用

  • ACEI和ARB可能作为多种PH表型的潜在治疗策略,但需进一步研究验证。
  • 醛固酮拮抗剂使用应视为疾病严重度的标志,而非独立增加死亡风险的因素。

局限性

  • 回顾性研究设计,可能存在残余混杂。
  • 使用退伍军人人群,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The renin-angiotensin-aldosterone system (RAAS) contributes to pulmonary hypertension (PH) pathogenesis. Although animal data suggest that RAAS inhibition attenuates PH, it is unknown if RAAS inhibition is beneficial in PH patients. RESEARCH QUESTION: Is RAAS inhibitor use associated with lower mortality in a large cohort of patients with hemodynamically confirmed PH? STUDY DESIGN AND METHODS: We used the Department of Veterans Affairs Clinical Assessment Reporting and Tracking Database to study retrospectively relationships between RAAS inhibitors (angiotensin converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and aldosterone antagonists [AAs]) and mortality in 24,221 patients with hemodynamically confirmed PH. We evaluated relationships in the full and in propensity-matched cohorts. Analyses were adjusted for demographics, socioeconomic status, comorbidities, disease severity, and comedication use in staged models. RESULTS: ACEI and ARB use was associated with improved survival in unadjusted Kaplan-Meier survival analyses in the full cohort and the propensity-matched cohort. This relationship was insensitive to adjustment, independent of pulmonary artery wedge pressure, and also was observed in a cohort restricted to individuals with precapillary PH. AA use was associated with worse survival in unadjusted Kaplan-Meier survival analyses in the full cohort; however, AA use was associated less robustly with mortality in the propensity-matched cohort and was not associated with worse survival after adjustment for disease severity, indicating that AAs in real-world practice are used preferentially in sicker patients and that the unadjusted association with increased mortality may be an artifice of confounding by indication of severity. INTERPRETATION: ACEI and ARB use is associated with lower mortality in veterans with PH. AA use is a marker of disease severity in PH. ACEIs and ARBs may represent a novel treatment strategy for diverse PH phenotypes.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lahm T, Hess E, Barón AE, et al. Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database. Chest. 2020. PMID: 33031831. doi:10.1016/j.chest.2020.09.258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。